Press release
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therapies from 10+ key Players, says DelveInsight
Spasticity Clinical Trials
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the Spasticity market.
The study provides an in-depth commercial and clinical review of pipeline candidates from preclinical research to marketed products. It includes comprehensive drug profiles covering mechanisms of action, clinical trial updates, regulatory milestones such as NDAs, and product development activities, including technological advancements, collaborations, licensing agreements, mergers and acquisitions, funding details, designations, and other key updates.
Download free sample report to discover emerging therapies @ https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=promotion&utm_campaign=apr
Key Highlights from the Spasticity Pipeline Report
• Global pharmaceutical companies are actively engaged in developing innovative Spasticity therapies, achieving notable progress in recent years.
• Leading players developing treatments for Spasticity include Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, and several others.
• Prominent emerging therapies in clinical development include Lu AG06466, DAXXIFY, IPN10200, SL-1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, among others each expected to influence the Spasticity treatment landscape significantly in the coming years.
Recent Spasticity Clinical and Regulatory Developments
• July 2025: A global Phase 2 trial, BALANCE-MSS-1 (NCT06782490), began enrolling approximately 200 adults with multiple sclerosis-related spasticity to evaluate Bristol Myers Squibb's oral candidate BMS-986368. The study spans the U.S., Europe, Australia, Canada, and Puerto Rico and is sponsored by Celgene, now operating under BMS.
•april 2025: The U.S. FDA cleared BlackfinBio's IND application for a Phase I/II study of BFB-101, an AAV gene therapy targeting hereditary spastic paraplegia type 47 (SPG47). The candidate holds orphan drug and rare pediatric disease designations, addressing AP4B1 gene mutations leading to progressive spasticity and developmental impairments in children.
• March 2025: BlackfinBio announced the submission of its IND application for the same AAV gene therapy designed for treating SPG47.
• January 2024: Neurotech International received approval from the Human Research Ethics Committee (HREC) and Australia's Therapeutic Goods Administration (TGA) to begin a Phase I/II trial of NTI164 in children with spastic cerebral palsy the most prevalent form of CP.
Get a Free Sample PDF Report to know more about Spasticity Pipeline Therapeutic Assessment-https://www.delveinsight.com/report-store/spasticity-pipeline-insight?utm_source=openpr&utm_medium=promotion&utm_campaign=apr
Overview of Spasticity
Spasticity is characterized by abnormal increases in muscle tone or stiffness, leading to impaired mobility, speech challenges, and gait abnormalities. It typically results from neurological damage or disruption within the brain or spinal cord that affects the pathways regulating muscle movement.
Emerging Spasticity Therapies in the Pipeline
Key candidates under development include:
• Lu AG06466 - Lundbeck
• DAXXIFY - Revance Therapeutics
• IPN10200 - Ipsen
• HU-014 - Huons
• SL-1002 - Saol Therapeutics
• MYOBLOC - Supernus Pharma
• SPARC1103 - Sun Pharma
• Tizanidine - Acorda Therapeutics
• Botulinum toxin type A - Merz Pharmaceuticals GmbH
• CORETOX® - Medy-Tox
• XP19986 SR1 - XenoPort, Inc.
• Intrathecal baclofen - Medtronic Neuro
Further Spasticity product details are provided in the report. Download the Spasticity pipeline report to learn more about the emerging Spasticity therapies - https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=promotion&utm_campaign=apr
Spasticity Drugs Routes of Administration (ROA)
The Spasticity pipeline includes therapies delivered through:
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Spasticity Drugs by Molecule Types
Products in development span a diverse range of molecule classes:
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies
Spasticity Therapeutic Assessments Covered
• Analysis by product type
• Stage-wise product segmentation
• Route of administration breakdown
• Stage-wise ROA evaluation
• Molecule type segmentation
• Stage-wise molecule classification
DelveInsight's report profiles 12+ candidates across all phases, including:
• Phase III (late-stage)
• Phase II (mid-stage)
• Phase I (early-stage)
• Preclinical and discovery assets
• Discontinued and inactive programs
Download Sample PDF Report to know more about Spasticity drugs and therapies - https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=promotion&utm_campaign=apr
Spasticity Pipeline Analysis
The report explores:
• Company-level therapeutic portfolios, including active and discontinued assets
• Stage-based analysis of therapeutic candidates
• Therapies categorized by route of administration, mechanism of action, monotherapy/combination status, and molecular structure
• Extensive details on partnerships, academia-industry collaborations, licensing agreements, and funding
• Data sourced from proprietary databases, clinical trial registries, corporate websites, SEC submissions, investor materials, conference proceedings, and validated third-party sources
Spasticity Market Drivers
• Rising incidence of stroke, MS, and brain injuries
• Growing R&D focus to identify effective and targeted Spasticity treatments
Spasticity Market Barriers
• High treatment costs
• Limited disease awareness in developing markets
• Additional challenges affecting therapy adoption
Scope of the Spasticity Market Report
• Coverage: Global
• Leading Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Medtronic Neuro, Daewoong Pharma, and others
• Key Therapies: Lu AG06466, DAXXIFY, IPN10200, SL-1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, etc.
• Therapeutic Coverage: Current and emerging therapies
• Market Dynamics: Detailed evaluation of drivers and barriers influencing the Spasticity market
Request for Sample PDF Report for Spasticity Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=promotion&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therapies from 10+ key Players, says DelveInsight here
News-ID: 4312387 • Views: …
More Releases from DelveInsight Business Research
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
Anti-CD19 Antibody Pipeline 2025: Therapies Under Investigation, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Anti-CD19 Antibody pipeline constitutes 12+ key companies continuously working towards developing 12+ Anti-CD19 Antibody treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Anti-CD19 Antibody Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD19 Antibody Market.
The Anti-CD19…
More Releases for Spasticity
Spasticity Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Spasticity is a motor disorder characterized by involuntary muscle stiffness, spasms, and exaggerated reflexes caused by damage to the central nervous system (CNS). It frequently occurs as a complication of stroke, multiple sclerosis (MS), cerebral palsy, traumatic brain or spinal cord injury, and other neurological conditions. Spasticity can severely impact mobility, daily functioning, and quality of life, making it a significant healthcare burden worldwide.
Treatment approaches combine pharmacological agents, intrathecal therapies,…
Muscle Spasticity Market Emerging Trends and Growth Prospects 2034
Introduction
Muscle spasticity is a condition characterized by involuntary muscle stiffness, spasms, and increased tone, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, stroke, or traumatic brain and spinal cord injuries. It significantly impacts mobility and quality of life, making effective management essential. With the rising incidence of neurological diseases and advancements in physiotherapy, drug therapies, and medical devices, the global muscle spasticity market is witnessing steady expansion.
According…
Spasticity Drugs Market Segments, Growth and Trends by Forecast by 2031
The report is segmented By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), Route of Administration (Oral, Intramuscular, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Get Sample Copy -https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10831
Major Companies operating in the Spasticity Drugs Market are:
Ipsen Pharma
Allergan
Acorda Therapeutics,…
Spasticity Drugs Top Companies Regional and Data Analysis to 2031
The Spasticity Drugs Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits.
Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Spasticity Drugs Market are:
• Ipsen Pharma
• Allergan
• Acorda Therapeutics, Inc.
• Merz Pharma
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Beximco Pharmaceuticals Ltd.
• Johnson & Johnson Private Limited
• Zydus Cadila
Contact Us:
If you have any queries about this report or if…
Spasticity Treatment Market Expecting Huge Demand in Upcoming Years
The Global Spasticity Treatment Market size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 4.9% to reach $8.8 Billion by 2034. Download now
The latest study released on the Global Spasticity Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Spasticity Treatment market study covers significant research data and proofs to be a handy resource…
Muscle Spasticity Market Growth, Research Report, Analysis & Trends 2023-2033
Muscle Spasticity Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years …
